Read Review Here: http://www.amazon.com/gp/product/B00028ZLU4/ref=as_li_ss_tl?ie=UTF8&tag=topbestbuy-20&linkCode=as2&camp=1789&creative=390957&creativeASIN=B00028ZLU4
Apparently some cats and dogs respond badly to this medication, but it works wonderfully for my cat. She
weighs just 10 pounds, so I give her half a tablet (I cut them apart in
a regular pill cutter) and any fleas she's picked up fall off and die.
My vet explained to me that the chemical in Capstar isn't recognized by
the animal's body - it just passes through without being absorbed and
broken down. It comes out as a gas through the pores of the skin, and
acts on the fleas like cyanide gas acts on people. It's instantly
lethal to the fleas. Unfortunately, when the fleas get the first whiff
of gas, they respond by biting REALLY HARD in a reflexive reaction.
Some cats and dogs who have several fleas may experience sudden very
hard bites in many areas of their bodies, which could account for the
jumping around and panting. It doesn't feel very good. Flea bites are
terrible under normal circumstances, and their
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Today Safe Kids Worldwide released a new research report that found while the death rate among children from poisoning has been cut in half since the late 1970s, the percentage of all child poisoning deaths due to medications has nearly doubled, from 36 percent to 64 percent.
Safe Storage, Safe Dosing, Safe Kids: A Report to the Nation on Safe Medication examines trends in morbidity and mortality of medication poisoning among children ages 14 and under. The report underscores the challenge of medication-related poisoning among children and offers solutions that will reverse the trends. Safe Kids also proposes specific roles that parents and other caregivers, industry, governments, and the medical community can play in improving medication safety through safe storage and safe dosing.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55155-safe-kids-worldwide-medication-safety-campaign-research-report
According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
CareFusion today launched the Pyxis® Enterprise System (ES) platform, a new generation of its industry-leading automated dispensing systems that will enable hospital customers to simplify and standardize the medication management process, both within a single facility and across an entire health system.
The new CareFusion Pyxis hardware and software brings key benefits to pharmacy, nursing and information technology (IT) departments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53365-carefusion-unveils-pyxis-automated-medication-dispensing-system
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
Many children and teens suffering from tachycardia, or rapid heart rate, have relied on medication to regulate their heart rhythms and control symptoms such as fatigue, dizziness and fainting spells. However, doctors at the Akron Children’s Hospital Arrhythmia Center have made great strides in curing tachycardia with minimally invasive procedures.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51056-akron-childrens-hospital-arrhythmia-tachycardia-cryoablation
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
Could migraine patients be doing more to get the most out of their medical visits? According to a new national survey released by the National Headache Foundation (NHF) and GlaxoSmithKline, the answer is yes. For the nearly 30 million migraine sufferers in the U.S., including six million treating with prescription medication, these survey results may have important implications.
The survey, conducted online in November 2010 by Harris Interactive, included 1,218 diagnosed migraine patients taking prescription medications for their migraine attacks as well as 533 physicians who treat between five and 10 migraine patients per week. The findings revealed disparities between what patients and physicians each reported typically discussing during office visits.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glaxosmithkline/48596/
The American Pain Foundation (APF) announced today the launch of new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as a part of its PainSAFE™ educational initiative. The new information will be launched with a national public service announcement (PSA) emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen, naproxen) and acetaminophen (Tylenol, APAP). APF is the nation’s largest consumer advocacy organization dedicated to people with pain.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/painfoundation/49865/
